'Orphan drug' development slow5th April 2006
A research study has found that development in Europe of drugs for serious but rare conditions - 'orphan drugs' - is progressing too slowly.
Researchers say that the low rate may be in part due to the paucity of European funds for companies willing to develop orphan drugs. Only 18 drugs were eventually approved out of the 255 products designated in four years by the European Union as 'orphan drugs' and entitled to special grants.
They call for urgent action, as there are still several thousand rare diseases awaiting therapy.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: 'Orphan drug' development slow
Author: Sue Knights
Article Id: 96
Date Added: 5th Apr 2006